Invention Grant
- Patent Title: NLRX1 ligands
-
Application No.: US17479337Application Date: 2021-09-20
-
Publication No.: US11548885B2Publication Date: 2023-01-10
- Inventor: Josep Bassaganya-Riera , Andrew Leber , Nuria Tubau-Juni , Raquel Hontecillas
- Applicant: Landos Biopharma, Inc.
- Applicant Address: US VA Blacksburg
- Assignee: Landos Biopharma, Inc.
- Current Assignee: Landos Biopharma, Inc.
- Current Assignee Address: US VA Blacksburg
- Agency: DeWitt LLP
- Agent Daniel A. Blasiole
- Main IPC: C07D413/14
- IPC: C07D413/14 ; A61P37/02

Abstract:
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat conditions such as autoimmune diseases, allergic diseases, chronic and/or inflammatory central nervous system diseases, chronic and/or inflammatory respiratory diseases, cancer, and infectious diseases. Exemplary conditions include multiple sclerosis, asthma, Alzheimer's disease, Parkinson's disease, neuroinflammation resulting from, for example, stroke, traumatic brain injury, or spinal cord injury, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and inflammatory bowel disease.
Public/Granted literature
- US20220089586A1 NLRX1 LIGANDS Public/Granted day:2022-03-24
Information query